Objective To evaluate the therapeutic effects of percutaneous ethanol intratumoral injection (PEIT) for treatment of small primary liver cancer (SPLC).Methods 240 patients with surgically or pathologically proved SPLC...Objective To evaluate the therapeutic effects of percutaneous ethanol intratumoral injection (PEIT) for treatment of small primary liver cancer (SPLC).Methods 240 patients with surgically or pathologically proved SPLC ( < 3 cm in diameter) were treated by PEIT ( under the guidance of B-ultrasound) . Of the" 240 patients, 163 had recurrent liver cancer, 55 had inoperable liver cancer because of cardiac, pulmonary, hepatic and renal dysfunctions or due to the close proximity of tumor to the major vessels, and 22 refused to receive surgical resection. In 40 patients who received surgical resection after PEIT treatment, the resected tumors were pathologically evaluated for necrotic status and the patients were followed up postoperatively.Results Postoperative 1-, 2- and 3-year survival rate of the 240 patients was 94.9% , 84.2% and 66.3% respectively. Conclusion PEIT can be used as a non-invasive treatment for SPLC, and preoperative PEIT appears to be helpful in reducing recurrence of postoperative liver cancer.展开更多
AIM： To compare intradermal （ID） and intramuscular （IM） booster doses, which have been used in healthy and high risk subjects, such as healthcare workers, haemodialysis patients, human immunodeficiency virus pati...AIM： To compare intradermal （ID） and intramuscular （IM） booster doses, which have been used in healthy and high risk subjects, such as healthcare workers, haemodialysis patients, human immunodeficiency virus patients, and renal transplant recipients unresponsive to initial hepatitis B vaccination, in celiac individuals. METHODS： We conducted our study on 58 celiac pa- tients, vaccinated in the first year of life, whose blood analysis had showed the absence of protective hepati- tis B virus （HBV） antibodies. All patients had received the last vaccine injection at least one year before study enrolment and they had been on a gluten free diet for at least 1 year. In all patients we randomly performed an HBV vaccine booster dose by ID or IM route. Thirty celiac patients were revaccinated with recombinant hepatitis B vaccine （Engerix B） 2 μg by the ID route, while 28 celiac patients were revaccinated with Engerix B 10 μg by the IM route. Four weeks after every boost- er dose, the anti-hepatitis B surface （HBs） antibody titer was measured by an enzyme-linked immune- adsorbent assay. We performed a maximum of three booster doses in patients with no anti-HBs antibodies after the first or the second vaccine dose. The cut off value for a negative anti-HBs antibody titer was 10 IU/L.Patients with values between 10 and 100 IU/L were considered ＂low responders＂ while patients with an antibody titer higher than 1000 IU/L were considered ＂high responders＂. RESULTS： No significant difference in age, gender, du- ration of illness, and years of gluten intake was found between the two groups. We found a high percent- age of ＂responders＂ after the first booster dose （ID = 76.7%, IM = 78.6%） and a greater increase after the third dose （ID = 90%, IM = 96.4%） of vaccine in both groups. Mloreover we found a significantly higher num- ber of high responders （with an anti-HBs antibody titer 〉 1000 IU/L） in the ID （40%） than in the IM （7.1%） group, and this difference was evident after the first booster dose of vaccination （P 〈 0.01）. No side effects were recorded in performing delivery of the vaccine by either the ID or IM route. CONCLUSION： Our study suggests that both ID and IM routes are effective and safe options to administer a booster dose of HBV vaccine in celiac patients. Howev- er the ID route seems to achieve a greater number of high responders and to have a better cost/benefit ratio.展开更多
Objection： To study the relationship between different doses and biological effect of 32p-glass microspheres （32P-GMS） by percutaneous intra-tumor injection at different times and provide proofs of theory for clini...Objection： To study the relationship between different doses and biological effect of 32p-glass microspheres （32P-GMS） by percutaneous intra-tumor injection at different times and provide proofs of theory for clinical therapy. Methods： 36 Zealand rabbits and Vx-2 were used to establish the animal model of liver tumor. Six groups were randomly designed. The suspension of different radiative doses of 32p-GMS combined with lipiodol-ultrafluid （0.1 mL） was respectively injected by percutaneous intra-tumor. The tumor tissues were examined by light microscope. MRI examination of liver tumors were performed before and after the injection. Results： C and D groups were observed that the tumor volume was decreased and the rate of restrained tumor was gradually increased after injection of 32p-GMS. The living tumor tissues of E group completely disappeared after the injection for two weeks. MRI examination showed that the tumor signal of E group was equal as T2 as the signal of normal liver parenchyma. The living tumor tissues were not found in F group after the injection for three weeks. Conclusion： 111 MBq was the best radiative dose of ~2p-GMS for treatment of 1 cm liver cancer by percutaneous intra-tumor injection. MRI examination was very valuable to evaluate the result and follow up after the injection to treat liver cancer.展开更多
Objective:To investigate nephroprotective effec ts of a mixture of 8 L-amino acids on renal ischemia-reperfusion injury and it s effects on renal endothelin-1 (ET-1). Methods:The mixture of 8 L-amino acids includes gl...Objective:To investigate nephroprotective effec ts of a mixture of 8 L-amino acids on renal ischemia-reperfusion injury and it s effects on renal endothelin-1 (ET-1). Methods:The mixture of 8 L-amino acids includes glycine, alan ine, threonine, serine, valine, leucine, isoleucine and proline. Acute ischemic renal injury was induced by clamping renal pedicle for 45 minutes in rats. Sixt y male Sprague-Dawley rats were randomly divided into 3 groups: a sham-operate d group (Group A, n=8), a control group (Group B, n=26) and an amino acid-treat ed group (Group C, n=26). Amino acids were infused at a rate of 1 ml·100g -1 ·h -1 I hour before ischemia and during 3 hours of the whole reperfusio n. The serum creatinine values, BUN levels, creatinine clearance, urine sodium & potassium excretion, urine lactate dehydrogenase (LDH), the rate of urine flow and histological examination were measured. Renal ET-1 levels were assayed wit h radioimmunological assay (RIA) Results: The creatinine clearance was 471.0 μl/min ± 121 .5 μl/min in Group C and 227.0 μl/min± 27.0 μl/min in Group B 3 ho urs after reperfusion, P< 0.01 ). The urine flow rate w as 63.6 μl/min± 15.2 μl/min in Group C and 24.3 μl/min± 7.7 μ l/min in Group B, P< 0.01 ) 1.5 hours after reperfu sion. The serum creatinine was 85.0 μl/min± 7.7 μmol/L and BUN concent ration 11.4 mmol/L ± 3.9 mmol/L in Group C and 112.7 μmol/L± 19.5 μmol/L and 20.7 mmol/L± 6.6 mmol/L respectively in Group B after 24 hours of reperfusion (P< 0.05 ) . The mean histological score by standards of Paller in kidneys was 108.7 ± 15.7 in Group C, and 16 8.8 ± 14.8 in Group B (P< 0.01 ).The renal ET-1 lev els 15 minute and 3 hours after reperfusion were 7.2 pg/mg± 0.8 pg/mg an d 9.6 pg/ml± 1.0 pg/ml in Group C , and 10.1 pg/ml± 2.8 pg/ml a nd 13.0 pg/ml± 2.7 pg/ml in Group B (P< 0.01 ). Conclusions:The mixture of 8 L-amino acids can provide remar kable protection against renal ischemia-reperfusion injury in rats. This may as sociate with attenuation of renal ET-1 disorder.展开更多
文摘Objective To evaluate the therapeutic effects of percutaneous ethanol intratumoral injection (PEIT) for treatment of small primary liver cancer (SPLC).Methods 240 patients with surgically or pathologically proved SPLC ( < 3 cm in diameter) were treated by PEIT ( under the guidance of B-ultrasound) . Of the" 240 patients, 163 had recurrent liver cancer, 55 had inoperable liver cancer because of cardiac, pulmonary, hepatic and renal dysfunctions or due to the close proximity of tumor to the major vessels, and 22 refused to receive surgical resection. In 40 patients who received surgical resection after PEIT treatment, the resected tumors were pathologically evaluated for necrotic status and the patients were followed up postoperatively.Results Postoperative 1-, 2- and 3-year survival rate of the 240 patients was 94.9% , 84.2% and 66.3% respectively. Conclusion PEIT can be used as a non-invasive treatment for SPLC, and preoperative PEIT appears to be helpful in reducing recurrence of postoperative liver cancer.
文摘AIM： To compare intradermal （ID） and intramuscular （IM） booster doses, which have been used in healthy and high risk subjects, such as healthcare workers, haemodialysis patients, human immunodeficiency virus patients, and renal transplant recipients unresponsive to initial hepatitis B vaccination, in celiac individuals. METHODS： We conducted our study on 58 celiac pa- tients, vaccinated in the first year of life, whose blood analysis had showed the absence of protective hepati- tis B virus （HBV） antibodies. All patients had received the last vaccine injection at least one year before study enrolment and they had been on a gluten free diet for at least 1 year. In all patients we randomly performed an HBV vaccine booster dose by ID or IM route. Thirty celiac patients were revaccinated with recombinant hepatitis B vaccine （Engerix B） 2 μg by the ID route, while 28 celiac patients were revaccinated with Engerix B 10 μg by the IM route. Four weeks after every boost- er dose, the anti-hepatitis B surface （HBs） antibody titer was measured by an enzyme-linked immune- adsorbent assay. We performed a maximum of three booster doses in patients with no anti-HBs antibodies after the first or the second vaccine dose. The cut off value for a negative anti-HBs antibody titer was 10 IU/L.Patients with values between 10 and 100 IU/L were considered ＂low responders＂ while patients with an antibody titer higher than 1000 IU/L were considered ＂high responders＂. RESULTS： No significant difference in age, gender, du- ration of illness, and years of gluten intake was found between the two groups. We found a high percent- age of ＂responders＂ after the first booster dose （ID = 76.7%, IM = 78.6%） and a greater increase after the third dose （ID = 90%, IM = 96.4%） of vaccine in both groups. Mloreover we found a significantly higher num- ber of high responders （with an anti-HBs antibody titer 〉 1000 IU/L） in the ID （40%） than in the IM （7.1%） group, and this difference was evident after the first booster dose of vaccination （P 〈 0.01）. No side effects were recorded in performing delivery of the vaccine by either the ID or IM route. CONCLUSION： Our study suggests that both ID and IM routes are effective and safe options to administer a booster dose of HBV vaccine in celiac patients. Howev- er the ID route seems to achieve a greater number of high responders and to have a better cost/benefit ratio.
基金a grant from the Tianjin Municipal Commission of Science and Technology(No.003607111)
文摘Objection： To study the relationship between different doses and biological effect of 32p-glass microspheres （32P-GMS） by percutaneous intra-tumor injection at different times and provide proofs of theory for clinical therapy. Methods： 36 Zealand rabbits and Vx-2 were used to establish the animal model of liver tumor. Six groups were randomly designed. The suspension of different radiative doses of 32p-GMS combined with lipiodol-ultrafluid （0.1 mL） was respectively injected by percutaneous intra-tumor. The tumor tissues were examined by light microscope. MRI examination of liver tumors were performed before and after the injection. Results： C and D groups were observed that the tumor volume was decreased and the rate of restrained tumor was gradually increased after injection of 32p-GMS. The living tumor tissues of E group completely disappeared after the injection for two weeks. MRI examination showed that the tumor signal of E group was equal as T2 as the signal of normal liver parenchyma. The living tumor tissues were not found in F group after the injection for three weeks. Conclusion： 111 MBq was the best radiative dose of ~2p-GMS for treatment of 1 cm liver cancer by percutaneous intra-tumor injection. MRI examination was very valuable to evaluate the result and follow up after the injection to treat liver cancer.
文摘Objective:To investigate nephroprotective effec ts of a mixture of 8 L-amino acids on renal ischemia-reperfusion injury and it s effects on renal endothelin-1 (ET-1). Methods:The mixture of 8 L-amino acids includes glycine, alan ine, threonine, serine, valine, leucine, isoleucine and proline. Acute ischemic renal injury was induced by clamping renal pedicle for 45 minutes in rats. Sixt y male Sprague-Dawley rats were randomly divided into 3 groups: a sham-operate d group (Group A, n=8), a control group (Group B, n=26) and an amino acid-treat ed group (Group C, n=26). Amino acids were infused at a rate of 1 ml·100g -1 ·h -1 I hour before ischemia and during 3 hours of the whole reperfusio n. The serum creatinine values, BUN levels, creatinine clearance, urine sodium & potassium excretion, urine lactate dehydrogenase (LDH), the rate of urine flow and histological examination were measured. Renal ET-1 levels were assayed wit h radioimmunological assay (RIA) Results: The creatinine clearance was 471.0 μl/min ± 121 .5 μl/min in Group C and 227.0 μl/min± 27.0 μl/min in Group B 3 ho urs after reperfusion, P< 0.01 ). The urine flow rate w as 63.6 μl/min± 15.2 μl/min in Group C and 24.3 μl/min± 7.7 μ l/min in Group B, P< 0.01 ) 1.5 hours after reperfu sion. The serum creatinine was 85.0 μl/min± 7.7 μmol/L and BUN concent ration 11.4 mmol/L ± 3.9 mmol/L in Group C and 112.7 μmol/L± 19.5 μmol/L and 20.7 mmol/L± 6.6 mmol/L respectively in Group B after 24 hours of reperfusion (P< 0.05 ) . The mean histological score by standards of Paller in kidneys was 108.7 ± 15.7 in Group C, and 16 8.8 ± 14.8 in Group B (P< 0.01 ).The renal ET-1 lev els 15 minute and 3 hours after reperfusion were 7.2 pg/mg± 0.8 pg/mg an d 9.6 pg/ml± 1.0 pg/ml in Group C , and 10.1 pg/ml± 2.8 pg/ml a nd 13.0 pg/ml± 2.7 pg/ml in Group B (P< 0.01 ). Conclusions:The mixture of 8 L-amino acids can provide remar kable protection against renal ischemia-reperfusion injury in rats. This may as sociate with attenuation of renal ET-1 disorder.
